![Adam Koppel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Adam Koppel
Director/Board Member at
Cerevel Therapeutics LLC
Profile
Adam M.
Koppel is currently Director at Cardurion Pharmaceuticals, Inc., Cerevel Therapeutics LLC, Cerevel Therapeutics, Inc., Areteia Therapeutics, Inc., and Kailera Therapeutics, Inc. He is Managing Director at Brookside Capital Partners, Inc. He serves as Trustee at Newton-Wellesley Hospital Corp.
and the Museum of Science.
Formerly, Dr. Koppel was Chairman at BCLS Acquisition Corp.
from 2020 to 2022.
He was Managing Director at Bain Capital Public Equity LP from 2011 to 2014.
He served as Independent Director at PTC Therapeutics, Inc. (2013–2017), ViaCyte, Inc. (2018–2021), Dicerna Pharmaceuticals, Inc. (2017–2021), Foghorn Therapeutics, Inc. (2017–2024), Trevena, Inc. (2014–2018), Aptinyx, Inc. (2017–2023), Solid Biosciences, Inc. (2017–2022 and 2022–2024), and Cerevel Therapeutics Holdings, Inc. (2018–2024).
He was Director at Temple Beth Elohim (2014–2017) and AavantiBio, Inc. He was Chief Strategy Officer & EVP-Business Development at Biogen, Inc. (2015–2016).
He worked as Associate Principal at McKinsey & Co., Inc. (2000–2003).
He held the position of Principal at Altus Pharmaceuticals, Inc. He was Trustee at Newton-Wellesley Health Care System, Inc. Education includes an MBA from The Wharton School of the University of Pennsylvania (2000), an undergraduate degree from Harvard University (1991), and a doctorate from the University of Pennsylvania Medical Center (1999).
Adam Koppel active positions
| Companies | Position | Start |
|---|---|---|
Bain Capital Life Sciences LP
 Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences invests in public and private companies located across the globe. The firm focuses on biopharmaceutical, specialty pharmaceuticals, medical device, diagnostic and life science technology sectors. It provides financing for buyout and growth stage capital requirements with an investment size of USD 25 - 100 million. | Private Equity Investor | 01/03/2003 |
Cerevel Therapeutics LLC
 Cerevel Therapeutics LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops drugs to treat disorders of central nervous system | Director/Board Member | - |
Newton-Wellesley Hospital Corp.
 Newton-Wellesley Hospital Corp. Hospital/Nursing ManagementHealth Services Provides health care services | Director/Board Member | - |
Museum of Science
 Museum of Science Other Consumer ServicesConsumer Services Operates as a museum | Director/Board Member | - |
Cardurion Pharmaceuticals, Inc.
 Cardurion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of heart failure and cardiovascular diseases | Director/Board Member | - |
Areteia Therapeutics, Inc.
 Areteia Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company | Director/Board Member | - |
Cerevel Therapeutics, Inc.
 Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapies | Director/Board Member | - |
Brookside Capital Partners, Inc.
 Brookside Capital Partners, Inc. Investment ManagersFinance Brookside Capital invests in small and middle market companies located in Canada with revenue size of USD 15 – 75 million. The firm focuses on business services, unique consumer & industrial products and services supporting infrastructure. It participates in growth equity, buyouts and recapitalizations with investment size of USD 5 – 25 million. The firm acquires majority and minority interests, and it takes a seat on the board seat. | Private Equity Investor | - |
Former positions of Adam Koppel
| Companies | Position | End |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Director/Board Member | 29/12/2024 |
| ░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░░░░░ ░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Training of Adam Koppel
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
91
1st degree connections
27
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 27 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Bain Capital Public Equity LP
 Bain Capital Public Equity LP Investment ManagersFinance Bain Capital Public Equity employs long/short equity strategies that combine rigorous bottom-up, fundamental research with analytical portfolio construction to identify and capitalize on opportunities across the global equity markets. The firm seeks to achieve isolate alpha and generate attractive returns over a full market and industry cycle with low correlation to the equity markets. Their investment advisory activity focuses on advising the Public Equity Funds on investments in securities of publicly traded companies that offer opportunities to realize substantial long-term appreciation. Bain Capital Public Equity typically makes investments in securities at prices it believes to be below their intrinsic value based on a company’s normalized cash flow, growth potential and/or asset value. | Finance |
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology Develops transformative medicines for people with serious diseases | Health Technology |
Dicerna Pharmaceuticals, Inc.
 Dicerna Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that focuses on discovering, developing and commercializing medicines for chronic liver diseases | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Altus Pharmaceuticals, Inc.
 Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops therapeutic products for gastrointestinal and metabolic diseases | Health Technology |
Newton-Wellesley Hospital Corp.
Newton-Wellesley Hospital Corp. Hospital/Nursing ManagementHealth Services Provides health care services | Health Services |
Museum of Science
Museum of Science Other Consumer ServicesConsumer Services Operates as a museum | Consumer Services |
Trevena, Inc.
 Trevena, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by central nervous system | Health Technology |
Temple Beth Elohim
 Temple Beth Elohim Miscellaneous Commercial ServicesCommercial Services Provides community support services | Commercial Services |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Pennsylvania Medical Center
 University of Pennsylvania Medical Center Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aptinyx, Inc.
 Aptinyx, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops therapies to treat disorders of the brain and nervous system | Health Technology |
Solid Biosciences, Inc.
 Solid Biosciences, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that develops treatments through gene therapy for patients with duchenne disease | Health Technology |
Bain Capital Life Sciences LP
Bain Capital Life Sciences LP Investment ManagersFinance Bain Capital Life Sciences invests in public and private companies located across the globe. The firm focuses on biopharmaceutical, specialty pharmaceuticals, medical device, diagnostic and life science technology sectors. It provides financing for buyout and growth stage capital requirements with an investment size of USD 25 - 100 million. | Finance |
Foghorn Therapeutics, Inc.
 Foghorn Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops novel drugs to treat cancer and other serious medical disorders | Health Technology |
Cardurion Pharmaceuticals, Inc.
Cardurion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of heart failure and cardiovascular diseases | Health Technology |
Cerevel Therapeutics LLC
Cerevel Therapeutics LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops drugs to treat disorders of central nervous system | Health Technology |
BCLS Acquisition Corp.
 BCLS Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Cerevel Therapeutics Holdings, Inc.
 Cerevel Therapeutics Holdings, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops novel therapies for neurological and psychiatric disorders | Health Technology |
Aavantibio, Inc.
 Aavantibio, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops new gene therapies | Health Technology |
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapies | Health Technology |
Areteia Therapeutics, Inc.
Areteia Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company | Health Technology |
Newton-Wellesley Health Care System, Inc. | |
Brookside Capital Partners, Inc.
Brookside Capital Partners, Inc. Investment ManagersFinance Brookside Capital invests in small and middle market companies located in Canada with revenue size of USD 15 – 75 million. The firm focuses on business services, unique consumer & industrial products and services supporting infrastructure. It participates in growth equity, buyouts and recapitalizations with investment size of USD 5 – 25 million. The firm acquires majority and minority interests, and it takes a seat on the board seat. | Finance |
- Stock Market
- Insiders
- Adam Koppel
Choose MarketScreener 
